Why Doximity Stock Plummeted Today

Shares of the Doximity (NYSE: DOCS) -- the No. 1 digital platform for medical professionals -- are down 24% as of 11 a.m. ET on Friday after the company reported third-quarter earnings Thursday afternoon. Sales and earnings per share exceeded Wall Street's expectations, but management's guidance for 4% revenue growth in Q4 sent the stock down sharply. Doximity's sales growth has slowed from 23% in Q3 last year to 10% in Q3 this year, so the upcoming quarter's conservative guidance really spooked the markets. Making matters worse, net income declined from $75 million in Q3 2025 to $62 million this year as marketing expenses rose 27% and the company invested heavily in its AI infrastructure. That said, I think Doximity's long-term investment thesis remains intact. Most of this quarter's volatility comes from shorter-term issues. For example, pharmaceutical companies are among Doximity's largest customers because they advertise with the company. These pharma companies continue to battle industry-specific headwinds, with 16 of the 20 largest pharma companies recently signing most-favored-nation agreements, resulting in delayed bookings with Doximity as they waited for clarity. This delay looks bad right now, but board member Tim Cabral highlighted how this was merely a timing shift, explaining, "This is evident in our January pharma bookings growth rate, which is the best we've seen since going public." The sales slowdown in Q3 and Q4 shouldn't be a sign of a long-term problem.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool